Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB
Mandate

Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB

November 29, 2021 Employment and Benefits Commercial Agreements Intellectual Property IT, Telecommunications and Outsourcing M&A

Established in 2015, with headquarters in Stockholm, Spendency has grown into a leading spend analytics provider.

Connected directly to the clients’ ERP and/or procurement system, Spendency helps its customers to collect, enrich and normalise supplier data. Spendency serves a vast customer base of more than 100 customers and over 1,500 users. Through the acquisition, Onventis strategically expands its product offering within spend analytics.

Vinge’s team consisted of Filip Öhrner and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (Agreements), Karolina Fuhrman (GDPR/IT), Arvid Axelryd (IP) and Jessica Henning (VDR).

 

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026